

REMARKS

Favorable reconsideration of the subject patent application is respectfully requested in view of the above amendments and the following remarks. Following the amendments, claims 72-91 are pending in the application, with claims 72, 77, 82 and 87 being in independent format.

A Substitute Sequence Listing is being submitted herewith. The sequence listing has been amended to correct typographical errors. Specifically, SEQ ID NO: 4 and 8 have been amended to state that these are human, not mouse, sequences. Support for these amendments can be found, for example, at page 52, line 28 - page 53, line 8, of the specification as originally filed. In addition, applicants have determined that the amino acid sequence for human FGFR5 (SEQ ID NO: 8) provided in the originally filed sequence listing is incorrect and does not correspond to the correct sequence as originally filed in Fig. 10 of the application. SEQ ID NO: 8 has thus been amended to correspond to the sequence provided in Fig. 10.

Claims 1-71 have been cancelled from the application and claims 72-91 have been added. Newly added claims 72-81 are drawn to subject matter previously recited in cancelled claim 60, namely methods for enhancing an immune response in a patient by administering a composition comprising a polypeptide, wherein the polypeptide comprises either: (a) SEQ ID NO: 8, or (b) a sequence having at least 95% identity to SEQ ID NO: 8 wherein the polypeptide has the same functional properties as SEQ ID NO: 8. Newly added claims 82-91 are drawn to methods for enhancing an immune response in a patient by administering a composition comprising a fusion protein, wherein the fusion protein comprises either: (a) SEQ ID NO: 8, or (b) a sequence having at least 95% identity to SEQ ID NO: 8 wherein the sequence has the same functional properties as SEQ ID NO: 8. Support for claims 72-91 may be found in Example 15 (page 69, line 9 - page 71, line 7); at page 22, line 2 - page 24, line 31; at page 30, line 7 - page 31, line 7; at page 31, line 15 - page 33, line 15, and throughout the specification as originally filed. Additional data demonstrating the effectiveness of the inventive polypeptides and fusion proteins in the enhancement of immune responses is presented in the Declaration of Dr. Greg Murison submitted herewith for the Examiner's consideration.


It is urged that none of the above amendments constitute new matter. Furthermore, it is urged that these amendments are not being made for reasons of patentability, but rather to correct clerical errors in the specification and to focus the claims on subject matter presently of most

interest to the assignee of record. Applicants thus submit that these amendments do not give rise to prosecution history estoppel.

Applicants specifically reserve the right to pursue claims to subject matter canceled from the claims by the above amendments in related patent applications.

Every effort has been made to put the claims in condition for allowance. Early consideration and allowance of the presently pending claims is respectfully requested.

Respectfully submitted,


Janet Sleath
Registration No. 37,007

Date: September 8, 2004
SPECKMAN LAW GROUP PLLC

20601